Citadel Advisors
HCWB icon

Citadel Advisors’s HCW Biologics HCWB Stock Holding History

Citadel Advisors’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.39K Buy
4,347
+654
+18% +$3.38K ﹤0.01% 12770
2025
Q4 		$21.5K Buy
+3,693
New +$62.8K ﹤0.01% 12328
2024
Q3 		– Sell
-58
Closed -$8.98K – 14618
2024
Q2 		$8.98K Buy
+58
New +$17.1K ﹤0.01% 13158
2024
Q1 		– Sell
-43
Closed -$12.7K – 14919
2023
Q4 		$12.7K Buy
+43
New +$14.7K ﹤0.01% 12979

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's HCWB Position: Q1 2026 in Review

Citadel Advisors increased its HCW Biologics (HCWB) stake by 18% in Q1 2026, buying an estimated $3.38K and bringing the position to 4,347 shares worth $9.39K. The position accounts for ﹤0.01% of the portfolio, ranked #12770.

Citadel Advisors first reported a position in HCWB in Q4 2023 and has held it in 4 quarters since. The position peaked at $21.5K in Q4 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Citadel Advisors held 4,347 shares of HCW Biologics worth $9.39K as of Q1 2026.
  • Citadel Advisors bought 654 HCW Biologics shares in Q1 2026, an estimated $3.38K.
  • HCW Biologics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12770 holding.
  • Citadel Advisors first reported a position in HCW Biologics in Q4 2023 and has held it in 4 quarters since.
  • Citadel Advisors's HCW Biologics position peaked at $21.5K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.